

# Michigan MEDICATION SECTION IPRATROPIUM BROMIDE

Initial Date: 07/19/2023

Revised Date: 08/11/2023

Section: 9-28R

## Ipratropium Bromide

Pharmacological Category: Anticholinergic Agent

Routes: Nebulized

#### Indications:

- 1. Wheezing
- 2. Airway Constriction

#### Contraindications:

1. Hypersensitivity to atropine or its derivatives

#### **Expected effects:**

- 1. Decreased wheezing
- 2. Decreased respiratory distress

**Notes:** May be administered in conjunction with albuterol 2.5 mg/3 mL NS as a 'Duoneb'.

#### Side effects:

- 1. Palpitations
- 2. Dry Mouth
- 3. Anxiety

### **Dosing: ANAPHYLAXIS ALLERGIC REACTION**

Indication: Continued wheezing and/or airway constriction after administration of nebulized albuterol.

Adults and pediatrics administer:

1. Ipratropium 500 mcg/2.5 mL NS nebulized

#### **Dosing: ADULT RESPIRATORY DISTRESS**

Indication: Continued wheezing and/or airway constriction after administration of nebulized albuterol.

Adults administer:

1. Ipratropium 500 mcg/2.5 mL NS nebulized

#### Used in the Following Protocols

Anaphylaxis/Allergic Reaction (Section 1 General Treatment)
Respiratory Distress (Section 3 Adult Treatment)

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

Page 1 of 1